SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Dumb SEND IT

Dumb SEND IT ($DSIT) is gaining traction as a high-volatility meme coin on the Solana network, with community members actively discussing its potential for a weekend rally and coordinated "dumb sends" to drive market cap growth. Supporters are highlighting the active involvement of the developer, who is incentivizing engagement through periodic airdrops to holders while encouraging the community to ignore market dips and focus on long-term accumulation.

Algorand is a scalable, secure, and decentralized digital currency and smart contract platform. Its protocol uses a variation of Proof-of-Stake (PoS) called Pure PoS (PPoS) to secure the network and reach consensus on block production. Developers can build decentralized applications (dApps) using familiar programming languages, including Python, which Algorand supports natively. Its infrastructure enables various use cases, including payment systems, digital identity solutions, supply-chain tracking, and financial services. The protocol's architecture allows for tokenization of assets and the development of smart contracts, while its technical specifications support both retail users seeking basic transaction capabilities and enterprises requiring more, complex, blockchain solutions.

Algorand

Algorand is seeing increased social media attention as the community debates its long-term potential following recent academic recognition for its post-quantum security architecture. Investors are actively discussing the project's institutional utility and price action, with many using the current market movement as an opportunity to accumulate tokens while others remain skeptical about the asset's historical performance.

"What's Updog?" is a Community Led token.

UpDog

UpDog is generating significant community buzz through its long-standing presence on the Solana network, with holders actively promoting its organic growth and whale accumulation trends. The community remains highly engaged by leveraging the project's playful 'dad joke' branding to maintain visibility and momentum across various social platforms.

Nomad Foods Ltd. operates as a holding company, which manufactures and sells frozen foods for human consumption. The firm offers its products under the brands LUTOSA, la Cocinera, Birds Eye, Iglo, and Findus. The company was founded by Noam Gottesman and Sir Martin E. Franklin on April 1, 2014 and is headquartered in Woking, the United Kingdom.

Nomad Foods Limited

Nomad Foods is trending as investors weigh its attractive dividend yield, aggressive share buyback programs, and low valuation against sector-wide headwinds and concerns about debt levels. The community is actively debating whether these factors signal a deep-value opportunity or a long-term value trap in the frozen food space.

MGM Resorts International is a holding company, which engages in the ownership and operations of casino resorts. The firm's casino resorts offer gaming, hotel, convention, dining, entertainment, retail, and other resort amenities. It operates through the following business segments: Las Vegas Strip Resorts, Regional Operations, MGM China, and MGM Digital. The Las Vegas Strip Resorts segment operates the following casino resorts: Bellagio, MGM Grand Las Vegas, Mandalay Bay, The Mirage, Luxor, New York-New, Excalibur, Park MGM, and Circus Las Vegas. The Regional Operations segment consists of the following casino resorts: MGM Grand Detroit in Detroit, Michigan, Beau Rivage in Biloxi, Mississippi, Gold Strike Tunica in Tunica, Mississippi, Borgata in Atlantic City, New Jersey, MGM National Harbor in Prince George’s County, Maryland, and MGM Springfield in Springfield, Massachusetts. The MGM China segment includes MGM Macau and MGM Cotai. The MGM Digital segment focuses on the online gaming portfolio, which consists primarily of Leo Vegas, which is headquartered in Sweden and Malta. The company was founded by Kerkor Kerkorian on January 29, 1986 and is headquartered in Las Vegas, NV.

MGM Resorts International

MGM Resorts International is drawing attention following the submission of a significant 2.3 billion dollar proposal for a new casino license in New York, a move seen by the community as a key strategy to expand its East Coast footprint. While investors weigh this regulatory catalyst against broader economic concerns, discussions remain split between the stock's long-term potential in the gaming sector and the immediate impact of market-wide volatility on consumer discretionary spending.

Solana is a high-performance Layer 1 blockchain designed for mass adoption by providing a fast, secure, and low-cost environment for decentralized applications. It distinguishes itself by scaling globally without the use of complex sharding or multiple layers, instead maintaining a single, unified ledger to avoid liquidity fragmentation. This architecture allows it to process thousands of transactions per second with sub-second finality, often at a cost of less than a penny per transaction.  The network operates on a unique hybrid model that combines Proof of Stake with an innovation called Proof of History, which functions as a decentralized clock to timestamp transactions. This system reduces the need for constant node communication, allowing the Sealevel engine to run non-conflicting smart contracts in parallel across multiple CPU cores. Further efficiency is gained through the Gulf Stream protocol, which reduces confirmation times by forwarding transactions to validators before the current block is finished.  Founded in 2017 by Anatoly Yakovenko, Solana is now supported by the Switzerland-based Solana Foundation and significant institutional investors like Andreessen Horowitz and Polychain Capital. The platform’s native token, SOL, serves as the primary currency for paying transaction fees, participating in network governance, and securing the system through staking.   Solana has also seen significant institutional adoption ranging from spot Solana ETFs to major partnerships including Visa's 2025 launch of USDC settlement on the network and the tokenization of public equity by firms like Galaxy Digital.

Solana

Solana is currently seeing intense community activity driven by speculative interest in smaller memecoins and ecosystem tokens, with traders closely monitoring its price action against broader market volatility. Investors are actively debating the potential for long-term growth versus short-term price stagnation, fueled by ongoing discussions around staking incentives and the platform's role in the evolving RWA and memecoin landscapes.

The Aircoin memecoin was born from a viral Twitter post from March, 2014 which proclaimed the following:   Evolution: 1. Aircoin 2. Fartcoin 3. Artcoin  Aircoin was launched in August, 2025 and CTO'd twice, with the second CTO team bringing vast experience and expertise to the project. The team includes industry veterans and visual arts professionals.  Aircoin is destined for greatness as a premier memecoin on the BONK.fun platform.

aircoin

AIRCOIN is gaining attention for its focus on long-term conviction, with the community actively highlighting deep on-chain liquidity locks and a treasury-backed model that distinguishes it from short-lived memecoin trends. Investors are coalescing around the project's 'PvE' (Player vs. Everyone) narrative, emphasizing high holder retention and the team's track record as key drivers of stability.

Orca is the most user-friendly DEX on Solana.  Orca is one of the first general-purpose AMMs launched on Solana. Users can swap assets, provide liquidity, and earn yield through an easy-to-use interface. Projects can use Orca as a money-lego to easily integrate swapping, farming, or on-chain data into their dApp.  Orca strives to provide easy and effective financial tools for everyone, bringing DeFi to the masses.

Orca

Orca is experiencing significant volatility driven by a short squeeze following recent market events and high trading volume. The community is actively debating the token's upside potential within the Solana ecosystem, with many investors highlighting its role as a key decentralized exchange while others urge caution regarding pump-and-dump dynamics.

What is Amp?  Amp is described as the new digital collateral token offering instant, verifiable assurances for any kind of value transfer. Using Amp, networks like Flexa can quickly and irreversibly secure transactions for a wide variety of asset-related use cases.  How does Amp work?  Amp claims to offer a straightforward but versatile interface for verifiable collateralization through a system of collateral partitions and collateral managers. Where collateral partitions can be designated to collateralize any account, application, or even transaction, and carry balances which are directly verifiable on the Ethereum blockchain, collateral managers are smart contracts that can lock, release, and redirect collateral in these partitions as needed in order to support value transfer activities. Amp supports a wide variety of use cases for collateralization, and also introduces the concept of predefined partition strategies, which can enable special capabilities such as collateral models through which tokens can be staked without ever leaving their original address.

AMP Token

AMP is attracting intense community attention as traders speculate on the potential passage of the Clarity Act, which proponents believe will solidify the token's status as a digital commodity and unlock its utility for institutional payments. While many users remain optimistic about the project's long-term infrastructure role, the discussion is polarized by deep frustration over prolonged price stagnation, accusations of artificial volume manipulation, and skepticism regarding the timing of enterprise adoption.

Jupiter is a cryptocurrency exchange platform on the Solana blockchain, offering features such as token swapping, limit orders, dollar-cost averaging, and a bridge for asset transfers to Solana. It provides users with tools to find the best trading prices and includes a beta version for perpetual futures trading. Jupiter finds the best price route for your swap by aggregating all the major liquidity sources on Solana.

Jupiter

The community is actively rallying behind the Jupiter (JUP) ecosystem, with significant focus on the UPDOG meme token as it highlights its presence on the JUP strict list. Participants are emphasizing long-term community resilience and strategic accumulation while leveraging the platform's liquidity tools for trading.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Biotech ETF (BBC) Touches Fresh 52-Week High

Biotech ETF BBC hits a 52-week high, likely fueled by strong clinical trial results and rising M&A activity, and renewed risk-on sentiment.

A candlestick chart can be seen in a trading platform on a smartphone. Top U.S. firms announced record buybacks this year. (Photo by Silas Stein/picture alliance via Getty Images)

Why Did NGNE Stock Surge 25% In Pre-Market Today?

The company said that the U.S. Food and Drug Administration granted a key designation for its investigational gene therapy targeting Rett syndrome.

This $20 Biotech Stock Just Got An FDA Boost – And A $200 Price Target 

Equity

<ul class="summary-bullets"><li>Verekitug was generally well tolerated in the 478-patient study, supporting its safety profile.</li><li>Verekitug reduced asthma attacks by 56% with 100 mg, and 39% with 400 mg compared to placebo.</li><li>Upstream has begun planning Phase 3 studies.&nbsp;</li></ul>Shares of Upstream Bio Inc. (UPB) crashed more than 40% on Wednesday despite the company announcing positive top-line results from its Phase 2 VALIANT trial evaluating Verekitug in adults with severe asthma.<h2 class="st-heading-2">Details Of The Test</h2>Verekitug, which targets the thymic stromal lymphopoietin (TSLP) receptor, reduced annual asthma attacks by 56% with 100 mg and 39% with 400 mg compared to placebo. Patients also showed improved lung function. Patients received Verekitug every 12 weeks for the 100 mg dose or every 24 weeks for the 400 mg dose.&nbsp;Verekitug was generally well tolerated in the 478-patient study, supporting its safety profile. More than 90% of eligible participants have enrolled in the VALOUR long-term extension trial to further assess the treatment’s durability.“We intend to rapidly advance verekitug into Phase 3 trials in severe asthma and CRSwNP. In parallel, we also continue to progress verekitug in our ongoing Phase 2 VENTURE trial in patients with COPD, where we have enrolled more than 60% of patients to date,” said Rand Sutherland, MD, Chief Executive Officer of Upstream Bio.&nbsp;<h2 class="st-heading-2">Phase 3 Studies Update</h2>Upstream Bio structured the VALIANT trial with endpoints intended to support potential approval filings, and has begun planning Phase 3 studies in severe asthma and CRSwNP, with registrational trials expected after regulatory discussions.The results reportedly aligned exactly with Amgen’s (AMGN) Tezspire in effectiveness. The drug requires 210 milligrams every four weeks.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Despite the sharp intraday decline, retail sentiment for <a href="https://stocktwits.com/symbol/UPB">UPB</a> on Stocktwits turned ‘extremely bullish’ from ‘bearish’ a day earlier, amid ‘extremely high’ message volumes.One user said the market reaction was ‘unwarranted’.<stembedurl>https://stocktwits.com/stjernerogvann/message/644653420</stembedurl>Another user saw a buying opportunity.<stembedurl>https://stocktwits.com/lordBrian/message/644666591</stembedurl>Year-to-date, the stock has declined more than 40%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of a trending stock chart.

Why Did UPB Stock Plunge 40% Today?

The company announced positive top-line results from its Phase 2 VALIANT trial evaluating Verekitug in adults with severe asthma.

<ul class="summary-bullets"><li>The verbal ruling was delivered on January 15, without written reasons, the company said.</li><li>The company said it disagrees with the outcome and plans to seek a review by the Enlarged Board of Appeal once the written ruling is issued.</li><li>The company does not expect the ruling to impact outcomes of its patent infringement cases against Moderna.</li></ul>Arbutus Biopharma Corp. (ABUS) stock crashed more than 18% on Friday after the European Patent Office (EPO) revoked its patent following opposition proceedings brought by affiliates of Moderna and Merck.This marked the <a href="https://stocktwits.com/symbol/ABUS">ABUS stock’s</a> biggest intraday decline since July 2020.The verbal ruling was delivered on January 15 without written reasons, Arbutus said. The EPO ruling reverses two earlier decisions that had upheld an amended version of the patent EP 2279254. According to Google Patents, it covers “Novel lipid formulations for nucleic acid delivery.”The company said it disagrees with the outcome and plans to seek a review by the Enlarged Board of Appeal once the written ruling is issued. Arbutus acknowledged that the decision could affect certain European legal actions against Moderna, including a case in Switzerland and a proceeding before the Unified Patent Court in which the patent is being asserted.<a href="https://stocktwits.com/symbol/MRNA">Moderna</a> (MRNA) jumped 7%, while <a href="https://stocktwits.com/symbol/MRK">Merck</a> (MRK) traded 2% lower.<h2 class="st-heading-2">Impact Outside Europe</h2>Arbutus stressed that the revocation was based on the EPO’s “added matter” standard, which does not apply in other jurisdictions.As a result, the company does not expect the ruling to impact the timing or potential outcomes of its patent infringement cases against Moderna in the United States, Japan, or Canada, a separate Unified Patent Court case not involving the patent, or its ongoing litigation against Pfizer and BioNTech in the U.S.<h2 class="st-heading-2">Retail Reaction</h2>Despite the sharp intraday decline, retail sentiment on Stocktwits turned ‘bullish’ from ‘bearish’ amid ‘high’ message volumes.<img src="https://news.stocktwits-cdn.com/ABUS_jpg_f665738876.webp" alt="ABUS.jpg">One user sees the drop as an opportunity to take up fresh positions.<stembedurl>https://stocktwits.com/LS172/message/642060814</stembedurl>One user said it’s all noise and nothing has changed ‘other than the bad headline’.<stembedurl>https://stocktwits.com/EdDwg/message/642040053</stembedurl>The stock has gained around 20% over the past year.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/why-did-jfbr-stock-surge-today/cmUlvsnR4B0">Why This Penny Stock Is On Track To Gain For First Time In 10 Sessions</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Plug Power said it was impacted by the speed and development of hydrogen economy.

ABUS Stock On Track For Biggest Intraday Drop In Over 5 Years – What’s The Issue Around Its Patent In Europe?

The European Patent Office revoked its patent following opposition proceedings brought by affiliates of Moderna and Merck.

<ul class="summary-bullets"><li>The company announced pricing of pre-funded warrants to purchase an additional 1.375 million shares at $23.9999 per warrant.</li><li>Monte Rosa also provided underwriters with a 30-day option to purchase up to 1.875 million additional shares at the public offering price.</li><li>The transaction is expected to close by January 12, 2026.</li></ul>Shares of Monte Rosa Therapeutics (GLUE) remain on the retail radar this week after the company priced a $300 million underwritten public offering at a discount to its last closing price.&nbsp;At the time of writing, <a href="https://stocktwits.com/symbol/GLUE">GLUE stock</a> fell 0.7% in premarket trading on Friday.&nbsp;The offering includes 11.125 million shares of common stock priced at $24.00 per share, a 5.1% discount to Thursday’s close at $25.31. Monte Rosa Therapeutics also announced pricing of pre-funded warrants to purchase an additional 1.375 million shares at $23.9999 per warrant.In addition, Monte Rosa also provided the underwriters with a 30-day option to purchase up to 1.875 million additional shares at the public offering price, net of underwriting discounts and commissions. All shares and pre-funded warrants in the offering are being sold by the company.The transaction is expected to close on or about January 12, 2026, with Jefferies, TD Cowen, and Piper Sandler serving as joint book-running managers for the offering. The $300 million raise represents an upsizing from the $200 million offering announced earlier this week.<h2 class="st-heading-2">Stock On Retail Radar</h2>The stock has been in the limelight lately. On Wednesday, GLUE shares surged more than 50% in premarket, before paring some of the gains after the opening bell. The move followed the <a href="https://stocktwits.com/news-articles/markets/equity/why-did-glue-stock-surge-over-50-in-premarket-today-1/cmxzbnHR42E">release</a> of encouraging interim Phase 1 data for MRT-8102 showing strong anti-inflammatory effects in patients with elevated cardiovascular risk.In the study, C-reactive protein levels fell by 85% after four weeks of treatment, with most participants reaching levels associated with lower cardiovascular risk. The drug also delivered deep and sustained target engagement across multiple dose levels. Based on the results, the company plans to advance MRT-8102 into a Phase 2 study later this year.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Despite the premarket slide, retail sentiment on Stocktwits remained in the ‘extremely bullish’ zone over the past 24 hours, amid ‘extremely high’ message volumes. GLUE was among the top trending tickers at the time of writing.<img src="https://news.stocktwits-cdn.com/GLUE_jpg_c79d022259.webp" alt="GLUE.jpg">One user said that the offer price came in higher than expected.<stembedurl>https://stocktwits.com/JacquelineWilder431/message/641308567</stembedurl>Over the past year, GLUE stock has surged nearly 300%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/why-did-aqst-stock-plunge-40-in-pre-market-today/cmU2g5ER4df">Why Did AQST Stock Plunge 40% In Pre-Market Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.&nbsp;

GLUE Stock Slips Pre-Market After Pricing $300 Million Public Offer At Discount

The offering includes 11.125 million shares of common stock priced at $24.00 per share, a 5.1% discount to Thursday’s close at $25.31.

<ul class="summary-bullets"><li>94% of participants achieved CRP levels below 2 mg/L, a threshold associated with lower cardiovascular risk.</li><li>Safety data were favorable, with adverse events that were mild to moderate, self-resolving, and not dose-dependent.</li><li>The company expects partner Novartis to begin multiple Phase 2 studies of MRT-6160 in immune-mediated diseases.</li></ul>Shares of Monte Rosa Therapeutics (GLUE) surged more than 50% in pre-market trading on Wednesday after the company reported positive interim Phase 1 data for MRT-8102, highlighting strong anti-inflammatory effects in subjects with elevated cardiovascular disease risk.<a href="https://stocktwits.com/symbol/GLUE">GLUE stock</a> is on track to open at its highest level in more than four years.<h2 class="st-heading-2">Phase – 1 Highlights</h2>The NEK7-directed molecular glue degrader produced rapid and durable reductions in systemic inflammation, with C-reactive protein (CRP) levels falling by 85% after four weeks of treatment. Notably, 94% of participants achieved CRP levels below 2 mg/L, a threshold associated with lower cardiovascular risk.The randomized, placebo-controlled study included single and multiple ascending doses, as well as a Part 3 cohort enrolling subjects with obesity and elevated CRP. Across doses ranging from 5 mg to 400 mg, MRT-8102 demonstrated deep and sustained NEK7 degradation of roughly 80% to 90%.&nbsp;The treatment also led to significant reductions in inflammatory markers. Safety data were favorable, with adverse events that were mild to moderate, self-resolving, and not dose-dependent, and no increased risk of infection was observed.Based on these results, Monte Rosa has expanded the ongoing GFORCE-1 study to multiple dose levels, with additional data expected in the second half of 2026. The company plans to initiate a Phase 2 study in atherosclerotic cardiovascular disease later this year, while continuing to explore additional inflammatory and oncology indications.Monte Rosa also outlined several upcoming milestones across its immunology, inflammation, and oncology programs. It expects partner Novartis to begin multiple Phase 2 studies of MRT-6160 in immune-mediated diseases and plans to submit an investigational new drug (IND) application&nbsp;for a next-generation NEK7 program in 2026.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits flipped to ‘extremely bullish’ from ‘bearish’ a day earlier, amid ‘extremely high’ message volumes. GLUE was among the top trending tickers on the platform.<figure class="image"><img src="https://news.stocktwits-cdn.com/GLUE_jpg_c79d022259.webp" alt="GLUE.jpg" width="937" height="99"><figcaption>GLUE's Sentiment Meter and Message Volumes at Premarket on Jan. 7, 2026 | Source: Stocktwits</figcaption></figure>One user sees a strong rally if the stock can overcome resistance at $28.<stembedurl>https://stocktwits.com/MuchMillions/message/641056765</stembedurl>Over the past year, the stock has gained more than 120%.Read Also: <a href="https://stocktwits.com/news-articles/markets/equity/why-did-first-solar-stock-fall-5-in-premarket-today/cmxyC2bR4cD">Why Did First Solar Stock Fall 5% In Premarket Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Why Did GLUE Stock Surge Over 50% In Premarket Today?

Monte Rosa Therapeutics reported positive interim Phase 1 data for MRT-8102, showing significant anti-inflammatory effects in patients with elevated cardiovascular risk.

Can ETF Winners of Q4 of 2025 Rally in Q1 of 2026?

Q4's top ETF winners -- silver, biotech and lithium -- outpaced markets. Can SIVR, SLV, BBC and LITP extend gains into 2026?

The Zacks Analyst Blog Highlights LLY, EPHE, BBC, HELX, XHS and SURI

LLY, EPHE, BBC, HELX, XHS and SURI headline last week's top-performing ETFs as healthcare and biotech outperform a weak broader market.

Best-Performing ETFs of Last Week: Healthcare Rules

Healthcare and biotech led last week's winners, with EPHE, BBC, HELX, XHS and SURI topping ETF gains as markets slid on AI worries and Fed uncertainty.

Biotech ETFs Hovering Around a 52-Week: Here's Why 

Biotech is back! Regulatory tailwinds, cheaper valuations, and Fed cut hopes are boosting ETFs like XBI and IBB. Is the rebound just starting?

BBC
ETFis Series Trust I - Virtus LifeSci Biotech Clinical Trials ETF

Feed

News

Sentiment

Fundamentals

Info

Latest BBC News

BBCETFis Series Trust I - Virtus LifeSci Biotech Clinical Trials ETF